<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pediatric Drug Interactions Reference</title>
    <style>
        .container {
            max-width: 800px;
            margin: 0 auto;
            padding: 20px;
            font-family: Arial, sans-serif;
        }

        h1, h2, h3 {
            color: #2c3e50;
        }

        h1 {
            text-align: center;
            border-bottom: 2px solid #2c3e50;
            padding-bottom: 10px;
        }

        .interaction-card {
            margin: 20px 0;
            padding: 20px;
            background-color: #f8f9fa;
            border-left: 4px solid #2c3e50;
            border-radius: 4px;
        }

        .warning {
            background-color: #fff3cd;
            border: 1px solid #ffeeba;
            padding: 10px;
            margin: 10px 0;
            border-radius: 4px;
        }

        .recommendation {
            background-color: #d4edda;
            border: 1px solid #c3e6cb;
            padding: 10px;
            margin: 10px 0;
            border-radius: 4px;
        }

        .reference {
            font-size: 0.9em;
            color: #6c757d;
            border-top: 1px solid #dee2e6;
            margin-top: 10px;
            padding-top: 10px;
        }

        .citation {
            font-style: italic;
            margin-top: 5px;
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>Critical Drug Interactions in Pediatric Care</h1>
        
        <div class="interaction-card">
            <h2>Azole Antifungals and Immunosuppressants</h2>
            <div class="warning">
                <strong>Critical Interaction:</strong> Significant increases in immunosuppressant blood levels when combined with azole antifungals (especially voriconazole and posaconazole)
            </div>
            <div class="recommendation">
                <strong>Management:</strong>
                <ul>
                    <li>Reduce immunosuppressant dose by 30-50% when initiating azole therapy</li>
                    <li>Monitor immunosuppressant levels every 48-72 hours until stable</li>
                    <li>Consider alternative antifungal classes in high-risk patients</li>
                </ul>
            </div>
            <div class="reference">
                Source: Triazole antifungal drug interactions-practical considerations for excellent prescribing
                <div class="citation">Veringa A, et al. Br J Clin Pharmacol. 2024 Jan 31. PMID: 38629250</div>
            </div>
        </div>

        <div class="interaction-card">
            <h2>Oncology Drug Interactions</h2>
            <div class="warning">
                <strong>Critical Interaction:</strong> Multiple drug interactions in onco-hematological pediatric patients, particularly with supportive care medications
            </div>
            <div class="recommendation">
                <strong>Management:</strong>
                <ul>
                    <li>Regular monitoring of drug levels for medications with narrow therapeutic windows</li>
                    <li>Consider drug interaction databases for comprehensive screening</li>
                    <li>Implement standardized monitoring protocols</li>
                </ul>
            </div>
            <div class="reference">
                Source: Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients
                <div class="citation">Fernández de Palencia Espinosa MA, et al. Med Clin (Barc). 2014 Dec 9;143(11):478-83. PMID: 25204258</div>
            </div>
        </div>

        <div class="interaction-card">
            <h2>Transplant Medication Interactions</h2>
            <div class="warning">
                <strong>Critical Interaction:</strong> Complex interactions between immunosuppressants and antifungal prophylaxis in pediatric transplant recipients
            </div>
            <div class="recommendation">
                <strong>Management:</strong>
                <ul>
                    <li>Carefully evaluate transition between different azole antifungals</li>
                    <li>Adjust immunosuppressant dosing proactively</li>
                    <li>Regular therapeutic drug monitoring</li>
                </ul>
            </div>
            <div class="reference">
                Source: Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective
                <div class="citation">Fisher BT, et al. Journal of the Pediatric Infectious Diseases Society, Volume 13, Issue Supplement_1, March 2024, Pages S68–S77</div>
            </div>
        </div>
    </div>
</body>
</html>